SafeHeal Secures €35 Million in Series C Funding to Advance Colovac Device for Colorectal Surgery
• SafeHeal has raised an oversubscribed €35 million Series C financing round led by Solar Eclipse, with funds earmarked for completing its IDE pivotal study and preparing for commercial launch of Colovac.
• Colovac, a temporary endoluminal fecal bypass system, offers a less-invasive alternative to diverting ostomy for colorectal cancer patients, potentially eliminating the need for a second surgery and improving quality of life.
• The device has received FDA Breakthrough Designation status after successful studies in over 100 patients across the U.S., Europe, and Asia, positioning SafeHeal for significant advancement in colorectal cancer surgery.
© Copyright 2025. All Rights Reserved by MedPath